FI20041632A - Liukoisia CTLA-4-molekyyleja ja niiden käyttöjä - Google Patents

Liukoisia CTLA-4-molekyyleja ja niiden käyttöjä Download PDF

Info

Publication number
FI20041632A
FI20041632A FI20041632A FI20041632A FI20041632A FI 20041632 A FI20041632 A FI 20041632A FI 20041632 A FI20041632 A FI 20041632A FI 20041632 A FI20041632 A FI 20041632A FI 20041632 A FI20041632 A FI 20041632A
Authority
FI
Finland
Prior art keywords
molecules
soluble ctla
ctla
soluble
Prior art date
Application number
FI20041632A
Other languages
English (en)
Swedish (sv)
Other versions
FI120041B (fi
Inventor
Peter S Linsley
Jeffrey A Ledbetter
Nitin Damle
William Brady
Philip M Wallace
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of FI20041632A publication Critical patent/FI20041632A/fi
Application granted granted Critical
Publication of FI120041B publication Critical patent/FI120041B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI20041632A 1994-04-15 2004-12-20 Liukoisia CTLA4-molekyyleja ja niiden käyttöjä FI120041B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/228,208 US6090914A (en) 1991-06-27 1994-04-15 CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US22820894 1994-04-15

Publications (2)

Publication Number Publication Date
FI20041632A true FI20041632A (fi) 2004-12-20
FI120041B FI120041B (fi) 2009-06-15

Family

ID=22856248

Family Applications (2)

Application Number Title Priority Date Filing Date
FI951801A FI951801A (fi) 1994-04-15 1995-04-13 CTLA4-molekyylit ja IL4:sitovat molekyylit sekä näiden käyttö
FI20041632A FI120041B (fi) 1994-04-15 2004-12-20 Liukoisia CTLA4-molekyyleja ja niiden käyttöjä

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI951801A FI951801A (fi) 1994-04-15 1995-04-13 CTLA4-molekyylit ja IL4:sitovat molekyylit sekä näiden käyttö

Country Status (8)

Country Link
US (1) US6090914A (fi)
EP (2) EP1666498A3 (fi)
JP (2) JPH0847391A (fi)
AU (1) AU701310B2 (fi)
CA (1) CA2146895C (fi)
FI (2) FI951801A (fi)
IL (1) IL113343A (fi)
NO (1) NO322278B1 (fi)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685941B1 (en) * 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6084067A (en) * 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
US6824779B1 (en) * 1993-07-26 2004-11-30 Dana-Farber Cancer Institute, Inc. Methods for inhibiting the interaction of B7-2 with its natural ligand
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) * 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
EP0892643B2 (en) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US20060034844A1 (en) * 1996-12-04 2006-02-16 The Regents Of The University Of California Stimulation of T cells against self antigens using CTLA-4 blocking agents
KR19980066046A (ko) * 1997-01-18 1998-10-15 정용훈 고역가의 CTLA4-Ig 융합단백질
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
WO1999015552A1 (fr) * 1997-09-19 1999-04-01 Yoshitomi Pharmaceutical Industries, Ltd. Composes oligopeptidiques
EP0947582A1 (en) * 1998-03-31 1999-10-06 Innogenetics N.V. A polypeptide structure for use as a scaffold
WO2001008700A1 (en) * 1999-07-28 2001-02-08 Genetics Institute, Inc. Preventing immune-mediated abortion by inhibiting costimulation
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1165752A4 (en) * 1999-10-22 2003-02-05 Alexion Pharma Inc MODIFIED RECOMBINATION MOLECULE REGULATING HUMOR AND CELLULAR EFFECTOR FUNCTIONS OF THE IMMUNE SYSTEM
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
CA2411962A1 (en) 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
TR201807700T4 (tr) 2000-07-03 2018-06-21 Squibb Bristol Myers Co Çözünür CTLA4 mutant moleküllerinin kullanımları.
AU2008200400B2 (en) * 2001-01-17 2012-06-07 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
DE60225914T2 (de) * 2001-05-23 2009-07-23 Bristol-Myers Squibb Co. Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
AU2002357427A1 (en) * 2001-12-04 2003-06-17 Tegenero Ag Peptide or protein containing a c'-d loop of the cd28 receptor family
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
JP2005529873A (ja) 2002-04-12 2005-10-06 メダレックス インコーポレイテッド Ｃｔｌａ−４抗体を使用した治療の方法
RU2375077C2 (ru) * 2002-05-02 2009-12-10 Юниверсити Оф Коннектикут Хелт Сентер Использование белков теплового шока для повышения эффективности терапий антителами
WO2004029069A2 (en) * 2002-09-30 2004-04-08 Pfizer Products Inc. Hybridomas producing high levels of human sequence antibody
TWI312368B (en) * 2002-12-23 2009-07-21 Bristol Myers Squibb Compan Mammalian cell culture processes for protein production
CN100402660C (zh) * 2002-12-23 2008-07-16 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法中产物质量提高
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005016266A2 (en) * 2003-08-04 2005-02-24 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble ctla4 molecule
KR100545720B1 (ko) * 2004-05-31 2006-01-24 메덱스젠 주식회사 당화된 면역글로불린 및 이를 포함하는 면역접합체
US7453291B2 (en) * 2004-09-09 2008-11-18 The Regents Of The University Of California Switch linearized track and hold circuit for switch linearization
CA2603970A1 (en) * 2005-04-06 2006-10-12 Bristol-Myers Squibb Company Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules
UA97469C2 (uk) * 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
JP2009518446A (ja) 2005-12-07 2009-05-07 メダレックス インコーポレーティッド Ｃｔｌａ−４抗体投与量漸増レジメン
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
ES2439641T3 (es) 2005-12-20 2014-01-24 Bristol-Myers Squibb Company Composiciones y procedimientos de producción de una composición
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
EP2612868B1 (en) 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
NZ603059A (en) * 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
MX338825B (es) 2008-10-02 2016-05-03 Emergent Product Dev Seattle Proteinas de enlace a objetivos multiples de antagonistas de cd86.
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CN106432474A (zh) 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
CN103153332A (zh) 2010-09-28 2013-06-12 卡尔医疗有限公司 用于治疗血液恶性肿瘤的组合物和方法
JP6074435B2 (ja) 2011-10-26 2017-02-01 ナショナル キャンサー センター 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物
WO2013062365A2 (ko) * 2011-10-26 2013-05-02 국립암센터 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
WO2018195339A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
WO2024107029A1 (ko) * 2022-11-18 2024-05-23 서울대학교산학협력단 Ctla-4 변이체 및 키메라 항원수용체를 이용한 이중 유전자 이입 면역세포 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
WO1994028912A1 (en) * 1993-06-10 1994-12-22 The Regents Of The University Of Michigan Cd28 pathway immunosuppression

Also Published As

Publication number Publication date
EP1666498A3 (en) 2012-11-28
EP0682039A1 (en) 1995-11-15
NO951436D0 (no) 1995-04-12
FI951801A (fi) 1995-10-16
FI951801A0 (fi) 1995-04-13
JP2004248677A (ja) 2004-09-09
EP1666498A2 (en) 2006-06-07
CA2146895A1 (en) 1995-10-16
NO951436L (no) 1995-10-16
NO322278B1 (no) 2006-09-04
IL113343A0 (en) 1995-07-31
CA2146895C (en) 2012-08-07
AU701310B2 (en) 1999-01-28
US6090914A (en) 2000-07-18
FI120041B (fi) 2009-06-15
JPH0847391A (ja) 1996-02-20
IL113343A (en) 2006-09-05
AU1645895A (en) 1995-10-26

Similar Documents

Publication Publication Date Title
FI20041632A (fi) Liukoisia CTLA-4-molekyyleja ja niiden käyttöjä
FI973471A0 (fi) Pyratsol-4-yylibentsoyylijohdoksia ja niiden käyttö herbisideinä
FI961599A (fi) 1N-alkyyli-N-aryylipyrimidiiniamiineja ja niiden johdannaisia
EE9900014A (et) Erütromütsiinid ja nende valmistamise protsess
FI962055A (fi) Pariston jatkolaite ja siihen liittyvä menetelmä
FI953479A0 (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
DE59509753D1 (de) Elektrochrome dünnschichtsysteme und deren komponenten
FI951773A (fi) Alfa-animoalkaanihapot ja niiden pelkistymistuotteet
BR9506832A (pt) N-pirazolilanilinas e n-pirazolilaminopiridinas
FI972494A0 (fi) Järjestelmiä ja menetelmiä biologista hajottamista varten
DE69620243D1 (de) Haupt- und nebenstromfilter
EE9800054A (et) Pürasool-4-üül-bensoüüli derivaadid ja nende kasutamine herbitsiididena
FI971085A0 (fi) Uusia PKA:ta sitovia proteiineja ja näiden käyttömuotoja
DE69603226T2 (de) Jodkomplex und dessen Verwendung
KR960010685A (ko) 펩티드 및 그 용도
FI950561A (fi) Ryömykestävä rauta-kromi-alumiiniseos ja siitä valmistettu tuote
DE19648723B4 (de) 4-Aminophenol-Derivate
BR9608918A (pt) Ligantes de p-selectina e moléculas relacionadas e métodos
KR960015044A (ko) 액정표시소자
KR970002716U (ko) 액정표시소자
KR950025617U (ko) 액정표시소자
KR960024348U (ko) 액정표시소자
KR960005953U (ko) 액정표시소자
DE69231334T2 (de) Chimere trna lys-ribozym-moleküle
KR970032410U (ko) 범용화한 승합차

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120041

Country of ref document: FI

MA Patent expired